Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
expanded autologous adipose-derived adult stem cells
- Development stage
- Unknown
- Lead developer
- MacroPore Biosurgery
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular, Intramuscular, Subcutaneous, Intralesional, Intrathecal, Topical, Intradermal, Intracoronary
01
Overview
Expanded autologous adipose-derived adult stem cells (AdMSCs) represent a cell-based therapeutic modality where a patient's own mesenchymal stromal cells are extracted from adipose tissue, expanded ex vivo, and reintroduced to treat various inflammatory and degenerative conditions. These cells function through complex paracrine signaling, secreting immunomodulatory cytokines and growth factors that inhibit cell-mediated immune responses and promote tissue repair and angiogenesis. Key clinical programs include TiGenix's CX-401 for complex perianal fistulas in Crohn's disease and American CryoStem's ATCell for post-concussion syndrome and other regenerative applications. As an autologous therapy, it minimizes the risk of immune rejection, though it requires a personalized manufacturing process for each patient.
- Brand names
- ATCell
- Other names
- Expanded autologous adipose-derived adult stroma/stem cellseASCsautologous adipose-derived mesenchymal stem cellsAdMSCs
Beyond the preview
Go deeper on expanded autologous adipose-derived adult stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on expanded autologous adipose-derived adult stem cells.